XBiotech Stock (NASDAQ:XBIT)


OwnershipFinancialsChart

Previous Close

$2.56

52W Range

$2.09 - $7.24

50D Avg

$2.47

200D Avg

$2.86

Market Cap

$76.83M

Avg Vol (3M)

$106.36K

Beta

0.77

Div Yield

-

XBIT Company Profile


XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation, and True Human COVID-19 therapy for treating the COVID-19 mutant virus. The company was incorporated in 2005 and is headquartered in Austin, Texas.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

92

IPO Date

Apr 15, 2015

Website

XBIT Performance


XBIT Financial Summary


Dec 24Dec 23Dec 22
Revenue--$4.01M
Operating Income$-42.47M$-37.51M$-34.49M
Net Income$-38.53M$-24.56M$-32.90M
EBITDA$-42.47M$-35.77M$-31.88M
Basic EPS$-1.26$-0.81$-1.08
Diluted EPS$-1.26$-0.81$-1.08

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 17May 07, 17 | 8:30 AM
Q4 16Mar 16, 17 | 8:30 AM
Q3 16Nov 15, 16 | 8:30 AM

Peer Comparison


TickerCompany
LITSLite Strategy, Inc.
TCRXTScan Therapeutics, Inc.
CRVOCervoMed Inc.
ADAGAdagene Inc.
FBIOFortress Biotech, Inc.
NTRBNutriband Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
GANXGain Therapeutics, Inc.
ACETAdicet Bio, Inc.
RLMDRelmada Therapeutics, Inc.